Trial · NCT00093015
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA) | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
| PRIMARY | Time to All-cause Mortality or End Stage Renal Disease (ESRD) | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
| SECONDARY | Time to All-cause Mortality | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
| SECONDARY | Time to Cardiovascular Mortality | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
| SECONDARY | Time to Myocardial Infarction | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
| SECONDARY | Time to Cerebrovascular Accident | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
| SECONDARY | Time to Congestive Heart Failure | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
| SECONDARY | Time to End Stage Renal Disease | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
| SECONDARY | Rate of Decline in Estimated Glomerular Filtration Rate (eGFR) Relative to Baseline | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | Subjects were analyzed as randomized using all available eGFR measurements, except eGFR measurements measured after subjects develop ESRD since creatinine measurements were no longer reliable or meaningful for eGFR calculation. | mL/min/1.73m^2 | MEAN |
| SECONDARY | Change in Patient Reported Fatigue Relative to Baseline at Week 25 | Baseline and week 25 | Subjects with both the baseline and at least post-baseline measurement at week 25 for FACT-fatigue were included in the analysis and were analyzed as randomized. Last observation carried forward (LOCF) using last non-missing post-baseline value was used for missing post-baseline data for subjects who were still on study. | Units on a scale | MEAN |
| SECONDARY | Time to Hospitalization Due to Acute Myocardial Ischemia | Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first | The analysis followed intent-to-treat principles. Subjects were analyzed as randomized using all available follow-up information. | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00093015/outcomes